Purpose: In patients(pts) with aplastic anemia(AA), chronic iron overload due to multiple transfusion can lead to the cardiac hemochromatosis. The aim of this study was to elucidate whether deferasirox(Exjade짰), an oral iron-chelating agent, can prevent the cardiac dysfunction in chronic iron overloading condition. Methods: 21 AA pts(age 31짹8, M:F=12:9) were recruited and divided into two groups [Deferasirox responder(DR) group, serum ferritin level<1500mg after treatment and Deferasirox non-responder(DnR) group, serum ferrtin level���1500mg after treatment]. The serum ferritin level was measured regularly and deferasirox dosage was adjusted. Transthoracic echocardiography was performed 1st, 25th, 50th, 100th week and the parameters including left ventricular ejection fraction(LVEF), LV mass, left atrial(LA) volume and LV filling indexes were measured. Results: 1.Serum ferritin level was decreased from 3540.9짹2176.8mg/dL to 809.1짹455.9mg/dL in DR(p<0.05) and 6524.2짹2911.4mg/dL to 4290.4짹2640.8mg/dL in DnR(p<0.05) after treatment. 2. Serum ferritin level was not correlated with E/E��� before treatment, but it was positively correlated with E/E��� after treatment.(figure) 3. E/E��� was changed from 7.3짹1.6 to 6.9짹1.1 in DR and from 6.9짹1.1 to 8.6짹2.1 in DnR(p=0.041) 4. LA volume was changed from 46.2짹16.6mL to 47.8 짹11.6mL in DR and from 61.3짹17.9mL to 68.3짹 15.4mL in DnR(p=0.004). Conclusion: The iron-chelating agent, deferasirox prevents the deterioration of diastolic function in chronic iron overload.